Visit https://www.peervoice.com/PVK860 to view the entire programme with slides. After completing “Make It a Double? Expert Insights on the Role of Dual Immunotherapy Regimens in First-Line NSCLC Treatment”, participants will be able to: Discuss the latest evidence with immunotherapy (IO)-based combinations for first-line non–small-cell lung cancer (NSCLC) treatment; Interpret what these data mean for the management of patients with NSCLC in Canadian clinical practice.